Literature DB >> 26136161

Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome.

Lucília Pereira1, Sara Horta2, Rita Mateus2, Mafalda A Videira3.   

Abstract

Akt2 is a pivotal player in a complex web of signaling pathways controlling cell growth, proliferation, and survival. The deregulation or aberrations of Akt2 have been associated with tumor progression, metastatic spread, and, lastly, chemoresistance. The impairment of its activity has gained more attention because Akt2 is intertwined with a range of signaling paths, including the Phosphatidylinositol 3 kinase/Akt/Mammalian target of rapamycin (PI3K/mTOR) signaling axis, which are involved in macromolecules synthesis and metabolism. Here, we focus on Akt2 because of its involvement in the acquisition of stem cell-like properties, responsible for invasiveness and chemoresistance, also promoted by Twist. We also suggest therapeutic strategies targeting Akt2 to overcome the drawbacks of current cancer therapies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26136161     DOI: 10.1016/j.drudis.2015.06.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  13 in total

Review 1.  A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics.

Authors:  Yuhao Wang; Benjamin Bonavida
Journal:  Crit Rev Oncog       Date:  2018

Review 2.  Histone Lysine Methylation Modification and Its Role in Vascular Calcification.

Authors:  Ye-Chi Cao; Su-Kang Shan; Bei Guo; Chang-Chun Li; Fu-Xing-Zi Li; Ming-Hui Zheng; Qiu-Shuang Xu; Yi Wang; Li-Min Lei; Ke-Xin Tang; Wen-Lu Ou-Yang; Jia-Yue Duan; Yun-Yun Wu; Muhammad Hasnain Ehsan Ullah; Zhi-Ang Zhou; Feng Xu; Xiao Lin; Feng Wu; Xiao-Bo Liao; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

3.  MicroRNA-143-3p, up-regulated in H. pylori-positive gastric cancer, suppresses tumor growth, migration and invasion by directly targeting AKT2.

Authors:  Fang Wang; Jiatao Liu; Yanfeng Zou; Yang Jiao; Yawei Huang; Lulu Fan; Xiaoqiu Li; Hanqing Yu; Chengqun He; Wei Wei; Hua Wang; Guoping Sun
Journal:  Oncotarget       Date:  2017-04-25

4.  AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.

Authors:  Marina Riggio; María C Perrone; María L Polo; María J Rodriguez; María May; Martín Abba; Claudia Lanari; Virginia Novaro
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

Review 5.  Distinct functions of AKT isoforms in breast cancer: a comprehensive review.

Authors:  Nico Hinz; Manfred Jücker
Journal:  Cell Commun Signal       Date:  2019-11-21       Impact factor: 5.712

Review 6.  Novel Molecular Markers for Breast Cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Biomark Cancer       Date:  2016-03-13

7.  MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2.

Authors:  Yang Liu; Shu-Tao Zhu; Xiao Wang; Jun Deng; Wei-Hua Li; Peng Zhang; Bing-Shan Liu
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

8.  Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures.

Authors:  Marzia Dolcino; Andrea Pelosi; Piera Filomena Fiore; Giuseppe Patuzzo; Elisa Tinazzi; Claudio Lunardi; Antonio Puccetti
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

Review 9.  AKT-ions with a TWIST between EMT and MET.

Authors:  Huifang Tang; Daniela Massi; Brian A Hemmings; Mario Mandalà; Zhengqiang Hu; Andreas Wicki; Gongda Xue
Journal:  Oncotarget       Date:  2016-09-20

10.  PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.

Authors:  S Bonin; D Pracella; R Barbazza; I Dotti; S Boffo; G Stanta
Journal:  Dis Markers       Date:  2019-11-06       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.